Receptor Therapeutics Inc. – a MaRS tenant – has raised $500,000 from the OICR’s IPDC Program via its OncoTek Drug Delivery Inc. subsidiary.

The funds will be used to drive the preclinical development of the company’s PoLi-PTX technology – a drug delivery system for intraperitoneal ovarian cancer.  PoLi-PTX is intended to permit effective localized cancer therapy without the associated side-effects of traditional chemotherapy.

Read the news release here (PDF).


John McCulloch

John provides assistance to life sciences entrepreneurs in business strategy, management, intellectual property, financing and licensing. See more…